Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Oncología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 2
ClinicalTrials.gov
A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study of the Safety and Efficacy of the Oral NeuroKinin-1 Receptor Antagonist, GW679769 in Combination With Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea
INTERVENTIONAL
Inicio: 1 de dic de 2004
ID: NCT00104403
Completado
ClinicalTrials.gov
Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study
OBSERVATIONAL
Inicio: 27 de dic de 2016
ID: NCT02984423
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN)
INTERVENTIONAL
Inicio: 1 de ene de 2005
ID: NCT00106691
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
INTERVENTIONAL
Inicio: 10 de jun de 2018
ID: NCT03755791
Completado
Fase 3
ClinicalTrials.gov
Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment
INTERVENTIONAL
Inicio: 2 de jul de 2008
ID: NCT00688376
Completado
Fase 3
ClinicalTrials.gov
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
INTERVENTIONAL
Inicio: 1 de feb de 2010
ID: NCT01067976
Completado
Fase 3
ClinicalTrials.gov
A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 31 de jul de 2010
ID: NCT01120184
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
INTERVENTIONAL
Inicio: 18 de abr de 2018
ID: NCT03383458
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
INTERVENTIONAL
Inicio: 26 de oct de 2017
ID: NCT03106779
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.
INTERVENTIONAL
Inicio: 1 de jul de 2007
ID: NCT00471146
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Multi-center, Placebo-Controlled Trial of Sorafenib (BAY43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens for Advanced Disease
INTERVENTIONAL
Inicio: 1 de abr de 2009
ID: NCT00863746
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma
INTERVENTIONAL
Inicio: 11 de abr de 2018
ID: NCT03470922
Activo, no recluta
Fase 3
ClinicalTrials.gov
Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors
INTERVENTIONAL
Inicio: 6 de feb de 2020
ID: NCT04154956
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
INTERVENTIONAL
Inicio: 13 de dic de 2022
ID: NCT05668988
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
INTERVENTIONAL
Inicio: 5 de oct de 2018
ID: NCT03690388
Desconocido
Fase 3
ClinicalTrials.gov
Study to Evaluate the Safety and Effectiveness of an Immunobiological Drug (Anti SARS-CoV-2) in the Treatment of Coronavirus Disease 2019 (CoViD-19)
INTERVENTIONAL
Inicio: 1 de jun de 2021
ID: NCT04913779
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy
INTERVENTIONAL
Inicio: 20 de feb de 2024
ID: NCT06117774
Completado
Fase 3
ClinicalTrials.gov
An Open-Label, Multicenter Study to Assess the Safety of RO5185426 (Vemurafenib) in Patients With Metastatic Melanoma
INTERVENTIONAL
Inicio: 1 de mar de 2011
ID: NCT01307397
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 12 de feb de 2008
ID: NCT00567190
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer
INTERVENTIONAL
Inicio: 1 de mar de 2002
ID: NCT00034268
Anterior
1
...
59
60
61
...
434
Siguiente
Filtros